Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL/VOX
DRUG: SOF/VEL

Sponsor

Gilead Sciences